ReviewCells2024
Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review.
Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Causal risk and protective factors for rheumatoid arthritis: a comprehensive mendelian randomization systematic review and meta-analysis.Frontiers in genetics · 2026Pooled it
- Immune-mediated rheumatoid arthritis: from single-cell genomics to new therapies.Nature immunology · 2026Review
- Use of Artificial Intelligence in Rheumatoid Arthritis: Advancements and Novel Perspectives.Journal of clinical medicine · 2026Review
- Increasing proportion and more favourable outcomes of seronegative rheumatoid arthritis: analysis of the IORRA cohort from 2000 to 2021.Clinical rheumatology · 2026Article
- Revisiting osteoarthritis as an inflammatory disease: characterization of synovitis grading and synovial pathotypes in surgical specimens.Arthritis research & therapy · 2026Article
- Synovial Fluid Characteristics and Pain Recovery Trajectory Following Rehabilitation in Patients with Meniscal Tears: A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Clustering reveals diagnostic overlap between Still's disease and a hyperinflammatory subset of seronegative rheumatoid arthritis.Scientific reports · 2026Article
- Rheumatoid arthritis and gout: a rare combination or overlooked coexistence?Arthritis research & therapy · 2026Article
- Unfortunate Exposures of Patients with Rheumatoid Arthritis Amid the Negligence of the Healthcare System.International journal of preventive medicine · 2026Article
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
- Mechanistic Study of Yibi Decoction in Treating Rheumatoid ArthritisEndocrine, metabolic & immune disorders drug targets · 2026Article
- In vitro development and evaluation of chitosan-cellulose nanocrystal microspheres for controlled dexamethasone delivery in rheumatoid arthritis.Rheumatology international · 2025Article
- Biopsy-Driven Synovial Pathophenotyping in RA: A New Approach to Personalized Treatment.Journal of personalized medicine · 2025Review
- Platelet-rich plasma-contained drug delivery systems to treat orthopedic injuries.International journal of pharmaceutics: X · 2025Review
- Development and multi-center validation of machine learning models based on targeted metabolomics for rheumatoid arthritis.Journal of translational medicine · 2025Article
- RRM2 contributes to pathogenic phenotype of fibroblast-like synoviocytes by activating NF-κB signaling and inhibiting ferroptosis in rheumatoid arthritis.Journal of orthopaedic surgery and research · 2025Article
- A Lymphatic Perspective on Obesity and Inflammatory Arthritis: New Disease-Modifying Potential in Rheumatology.Journal of clinical medicine · 2025Article
- Early rheumatoid arthritis, two distinctive structural damage patterns revealed by MRI: an 8-year longitudinal study.European radiology · 2025Article
- Article
- Identifying Targets and Drugs for Rheumatoid Arthritis Stratified Therapy Using Mendelian Randomization and a Pretraining Model.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder which can lead to long-term joint damage and significantly reduced quality of life if not promptly diagnosed and adequately treated. Despite significant advances in treatment, about 40% of patients with RA do not respond to individual pharmacological agents and up to 20% do not respond to any of the available medications. To address this large unmet clinical need, several recent studies have focussed on an in-depth histological and molecular characterisation of the synovial tissue to drive the application of precision medicine to RA. Currently, RA patients are clinically divided into "seropositive" or "seronegative" RA, depending on the presence of routinely checked antibodies. Recent work has suggested that over the last two decades, long-term outcomes have improved significantly in seropositive RA but not in seronegative RA. Here, we present up-to-date differences in epidemiology, clinical features, and serological biomarkers in seronegative versus seropositive RA and discuss how histological and molecular synovial signatures, revealed by recent large synovial biopsy-based clinical trials, may be exploited to refine the classification of RA patients, especially in the seronegative group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.